Inhibitory effect of ramosetron on corticotropin releasing factor‐ and soybean oil‐induced delays in gastric emptying in rats

Background and Aim:  Symptoms of functional dyspepsia (FD) are highly prevalent in patients with irritable bowel syndrome (IBS). However, the effects of therapeutic agents for IBS on the pathophysiology of FD are unclear. In this study, therefore, we examined the effects of ramosetron, a serotonin 5‐HT3 receptor antagonist, on corticotropin releasing factor (CRF)‐ and soybean oil‐induced delays in gastric emptying of rats, in comparison with anti‐diarrheal agent and spasmolytics. The involvement of 5‐HT and the 5‐HT3 receptor in delayed gastric emptying was also evaluated.

[1]  M. Takei,et al.  Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. , 2011, European journal of pharmacology.

[2]  P. Bertrand,et al.  Serotonin release and uptake in the gastrointestinal tract , 2010, Autonomic Neuroscience.

[3]  H. Miwa,et al.  Analysis of the Gastrointestinal Symptoms of Uninvestigated Dyspepsia and Irritable Bowel Syndrome , 2009, Gut and liver.

[4]  K. Nozawa,et al.  TRPA1 agonists delay gastric emptying in rats through serotonergic pathways , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  W. Chey,et al.  An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome , 2008, The American Journal of Gastroenterology.

[6]  M. Sasamata,et al.  Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats. , 2008, European journal of pharmacology.

[7]  M. Sasamata,et al.  Effects of serotonin 5‐HT3 receptor antagonists on stress‐induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer , 2008, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[8]  A. Nishida,et al.  The effect of paroxetine on the pharmacokinetics, safety, and tolerability of ramosetron in healthy subjects , 2008, European Journal of Clinical Pharmacology.

[9]  M. Hongo,et al.  A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome , 2008, Scandinavian journal of gastroenterology.

[10]  M. Sasamata,et al.  Inhibitory effects of ramosetron, a potent and selective 5-HT3-receptor antagonist, on conditioned fear stress-induced abnormal defecation and normal defecation in rats: comparative studies with antidiarrheal and spasmolytic agents. , 2008, Journal of pharmacological sciences.

[11]  Lin Chang,et al.  FUNCTIONAL BOWEL DISORDERS , 2018, The American Journal of Gastroenterology.

[12]  D. Savastano,et al.  Intestinal nutrients elicit satiation through concomitant activation of CCK1 and 5-HT3 receptors , 2007, Physiology & Behavior.

[13]  M. Sasamata,et al.  Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. , 2007, Journal of pharmacological sciences.

[14]  E. Lindström,et al.  Functional CRF receptors in BON cells stimulate serotonin release. , 2007, Biochemical pharmacology.

[15]  M. R. Hayes,et al.  Serotonin-type 3 receptors mediate intestinal lipid-induced satiation and Fos-like immunoreactivity in the dorsal hindbrain. , 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

[16]  T. Dinan,et al.  Functional dyspepsia: are psychosocial factors of relevance? , 2006, World journal of gastroenterology.

[17]  J. Tack,et al.  Impact of Coexisting Irritable Bowel Syndrome on Symptoms and Pathophysiological Mechanisms in Functional Dyspepsia , 2004, American Journal of Gastroenterology.

[18]  Y. Taché,et al.  CRF1 receptor signaling pathways are involved in stress‐related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome , 2004, British journal of pharmacology.

[19]  M. Crowell,et al.  Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea , 2003, American Journal of Gastroenterology.

[20]  T. Tsuruo,et al.  Contribution of P‐glycoprotein to efflux of ramosetron, a 5‐HT3 receptor antagonist, across the blood‐brain barrier , 2002, The Journal of pharmacy and pharmacology.

[21]  N. Read,et al.  Food and hypersensitivity in functional dyspepsia , 2002, Gut.

[22]  M. A. Gülpınar,et al.  Enterogastric Brake In Rats With Segmental Bowel Resection: Role Of Capsaicin‐Sensitive Nerves , 2002, Clinical and experimental pharmacology & physiology.

[23]  M. Camilleri,et al.  Functional gastroduodenal disorders , 1999, Gut.

[24]  I. Hirotsu,et al.  Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. , 1999, Life sciences.

[25]  H. Raybould,et al.  PYY immunoneutralization does not alter lipid-induced inhibition of gastric emptying in rats , 1999, Regulatory Peptides.

[26]  B. Schneeman,et al.  Cholecystokinin and serotonin receptors in the regulation of fat-induced satiety in rats. , 1999, American journal of physiology. Regulatory, integrative and comparative physiology.

[27]  S. Fukudo,et al.  Involvement of the 5-HT3 receptor in CRH-induce defecation in rats. , 1998, The American journal of physiology.

[28]  S. Akuzawa,et al.  Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. , 1995, Japanese Journal of Pharmacology.

[29]  S. Higuchi,et al.  Metabolic Fate of Ramosetron Hydrochloride (2): Absorption, Distribution and Excretion after Oral Administration of 14C-Ramosetron Hydrochloride to Rats , 1995 .

[30]  K. Mousavizadeh,et al.  Effects of atropine, pirenzepine, clonidine, and morphine on biphasic response of rat gastric fundus to field stimulation. , 1994, General Pharmacology.

[31]  A. Megens,et al.  Loperamide. Survey of studies on mechanism of its antidiarrheal activity. , 1993, Digestive diseases and sciences.

[32]  S. Harasawa.  Effect of itopride hydrochloride on gastric emptying in chronic gastritis patients , 1993 .

[33]  Y. Taché,et al.  Central nervous system action of corticotropin-releasing factor to inhibit gastric emptying in rats. , 1987, The American journal of physiology.

[34]  J. Junien,et al.  Interactions of trimebutine with guinea‐pig opioid receptors , 1987, The Journal of pharmacy and pharmacology.